10x Genomics, Inc.

As of June 30, 2026, 10x Genomics Inc Class A carries a market capitalization of 78.99B, placing it among publicly traded companies globally. Its enterprise value stands at 70.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

10x Genomics Inc Class A's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, 10x Genomics Inc Class A has 130.28M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 7.18, and the price-to-book ratio stands at 5.48.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 70.72B versus a market cap of 78.99B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, 10x Genomics Inc Class A maintains a current ratio of 5.69, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A posted a negative return on equity (ROE) of -9.40, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.47, reflecting losses generated across the asset base. The company generates approximately 8.91M in revenue per employee across its workforce of 1,210.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.04 indicates how many times 10x Genomics Inc Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A recorded 4.11M in income tax expense. The company reported a pretax loss of -1.31B and -1.31B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 8, 2026, 10x Genomics Inc Class A's stock has gained approximately 470.74% over the past 52 weeks.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A generated 10.78B in revenue and converted that into -1.31B in net income, yielding earnings per share of -10.28. EBITDA reached -706.60M, while operating income came in at -1.60B.

As of June 30, 2026, 10x Genomics Inc Class A holds 9.64B in cash and equivalents against 1.38B in total debt, resulting in a net debt position of -8.78B. Total book value stands at 14.42B, with working capital of 9.72B providing operational flexibility.

10x Genomics Inc Class A produced 2.22B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -98.70M in capital expenditures, free cash flow totaled 2.12B - equivalent to 16.61 per share.

Over the twelve months ended June 30, 2026, 10x Genomics Inc Class A posted a gross margin of 70.03, reflecting its pricing power and cost economics. The operating margin of -14.88 and net profit margin of -12.18 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.74, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.06, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to 10x Genomics Inc Class A shareholders.

As of June 30, 2026, 10x Genomics Inc Class A has an Altman Z-Score of 12.04, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.